Please ENTER to search
Welcome to the core of API manufacturing. At SCL Lifesciences, we are proud to be your trusted partner as a CDMO/CMO in the domain of API manufacturing. In the complex world of pharmaceuticals, the journey can be challenging. That's why we are committed to simplifying this journey by providing high quality APIs, specialty and performance chemicals, and advanced intermediates. Our offerings include high-potent molecules to niche generics like Homatropine, Dexketoprofen, Atropine, and papaverine etc., backed by high compliance certifications.
As a leading API manufacturer, we understand the importance of reliable, time-bound delivery. We focus on customer service, flexibility, and delivering solutions that not only meet immediate needs but also ensure long-term success for our partner organization.
From raw material procurement, chemical synthesis, isolation, and purification, to QC and packaging, we offer unwavering commitment to quality and safety. Our unique value proposition lies in our strong backward integration, allowing us to manufacture key raw materials essential to our products. This ensures a seamless supply chain, guaranteeing superior quality and cost efficiency.
Our commercial APIs are distributed globally, from Europe, the United States to Japan, Korea, Brazil, Turkey, Russia, and CIS countries, as well as South & Central America, the Middle East, and North Africa. At our state-of-the-art Knowledge Centre in Hyderabad, we support critical stages of development and optimization, ensuring you can move forward confidently through each phase of development and market introduction.
View our complete API list to find the right solution for your pharmaceutical needs.
Therapeutic Area: Lipid Lowering Agent
Expected: Q3 2025
Therapeutic Area: Type-II Antidiabetic
Expected: Q2 2025
Therapeutic Area: Treatment of Anaemia due to CKD
Expected: Q3 2025
Therapeutic Area: Antidiabetic
Expected: Q4 2025
Therapeutic Area: Non-Steroidal Anti-Inflammatory Drug, or NSAID
Expected: Q3 2025
Therapeutic Area: Antiplatelet
Expected: Q3 2025
Therapeutic Area: Anti-inflammatory, analgesic, and wound healing properties
Expected: Q4 2025
Therapeutic Area: Direct oral anticoagulants (DOACs)
Expected: Q1 2026
Therapeutic Area: Azole antifungals
Expected: Q2 2026
Therapeutic Area: Treatment of relapsing multiple sclerosis and ulcerative colitis
Expected: Q4 2025
Therapeutic Area: Transthyretin kinetic stabilizer
Expected: Q1 2026
Therapeutic Area: Janus kinase (JAK)1-selective inhibitor
Expected: Q1 2026
Therapeutic Area: Potassium-competitive acid blockers (PCAB)
Expected: Q1 2026
Disclaimer: Products protected by valid patents are not offered for sale in countries where the sale of such products constitutes a patent infringement. The liability of any sale into such protected markets is at buyer's risk.
Among API manufacturing companies, we stand out for our commitment to innovation and reliability. If you are looking for an active pharmaceutical ingredient manufacturer then, our expertise ensures your success.
Find answers to the most commonly asked questions about our services.
Reference of the compliance list:
Browse through our related services that complement your needs and provide comprehensive solutions.
Request you to provide all details mentioned in the form along with your business requirement. It will help us route your query to the appropriate person.